dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada Frontiers The effect of DPP-4 inhibitors,

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Conclusions Small molecule GLP-1 receptor agonists represent an innovative advancement in the management of T2DM and obesity

The main differences across comparison categories are: Mechanism of Action: advantage goes to Retatrutide

Medicaid covers Wegovy in some capacity for chronic weight management in 14 states and a minority of employer insurance plans cover AOMs: perhaps only about 22% of US employers

10.1111/dom.16364 101 TianS.LeiY.ZhaoF.CheJ.WuY.LeiP.et al (2024)

Ozempic is FDA-approved to help with blood sugar management in people with diabetes, while Wegovy is approved for weight loss in people who are overweight or struggle with obesity